{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:37:15Z","timestamp":1791585435185,"version":"4.3.4"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004480","name":"Natural Science Foundation of Shanxi Province","doi-asserted-by":"publisher","award":["202103021223404, 202403021221260"],"award-info":[{"award-number":["202103021223404, 202403021221260"]}],"id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Primary large B-cell lymphoma of immune-privileged sites (IP-LBCL) encompasses a spectrum of relatively rare aggressive B-cell lymphomas, such as primary central nervous system lymphoma (PCNSL), primary testicular large B-cell lymphoma (PTL), and primary vitreoretinal large B-cell lymphoma (PVRL). Macroscopically, the development of IPI-LBCL may be associated with the dysfunction of meningeal lymphatic vessels (mLVs) and the perivascular channel system formed by astrocytes. Microscopically, mutation in MYD88 and CD79B genes plays a pivotal role in the pathogenesis of IP-LBCL. Pathological examination remains the cornerstone for establishing a diagnosis of IP-LBCL. Moreover, traditional imaging is now supplemented by a suite of advanced diagnostic methods, including cytological, genetic, immunological, multiple omics, and molecular biological, which collectively enhance the diagnostic accuracy of IP-LBCL. Despite these advancements, the high recurrence rates and attendant high mortality rates pose significant challenges to achieving long-term survival in IP-LBCL patients. However, the emergence of novel therapeutic agents, such as Bruton\u2019s tyrosine kinase inhibitors (BTKi), immune checkpoint inhibitors, immunomodulators, and anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy, has offered promising new avenues for the treatment of IP-LBCL, demonstrating remarkable anti-tumor efficacy in recent years. This review delves into the epidemiology, pathogenesis mechanisms, diagnosis approaches, therapeutic strategies, and prognosis factors associated with IP-LBCL. It meticulously examines the parallels and divergences between the National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) guidelines, enhancing the professional comprehension of the complexities inherent to IP-LBCL.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1533444","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T02:24:48Z","timestamp":1740536688000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Advances in primary large B-cell lymphoma of immune-privileged sites"],"prefix":"10.3389","volume":"16","author":[{"given":"Liao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiru","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuling","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020911","article-title":"Primary large B-cell lymphomas of immune-privileged sites","volume":"144","author":"Roschewski","year":"2024","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3198","article-title":"A retrospective study of 222 patients with newly diagnosed primary central nervous system lymphoma-outcomes indicative for improved survival overtime","volume":"41","author":"Bairey","year":"2023","journal-title":"Hematol Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41572-023-00439-0","article-title":"Primary central nervous system lymphoma","volume":"9","author":"Ferreri","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/ms9.0000000000001018","article-title":"Unusually aggressive primary testicular diffuse large B-cell lymphoma initially presenting as systemic disseminating metastases in older adult men: A case report","volume":"85","author":"Liu","year":"2023","journal-title":"Ann Med Surg (2012)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.21873\/cdp.10192","article-title":"Primary testicular lymphoma: single center experience","volume":"3","author":"Shah","year":"2023","journal-title":"Cancer Diagn Prognosis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008235","article-title":"Primary vitreoretinal lymphoma: A diagnostic and management challenge","volume":"138","author":"Soussain","year":"2021","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax4063","article-title":"Biological functions of lymphatic vessels","volume":"369","author":"Petrova","year":"2020","journal-title":"Sci (New York N.Y.)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10014-021-00414-1","article-title":"Insights in primary central nervous system lymphoma: A role for glymphatics","volume":"38","author":"Kumaria","year":"2021","journal-title":"Brain Tumor Pathol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1038\/s41467-022-30050-y","article-title":"The genomic and transcriptional landscape of primary central nervous system lymphoma","volume":"13","author":"Radke","year":"2022","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.3390\/cancers13164049","article-title":"Testicular diffuse large B-cell lymphoma-clinical, molecular, and immunological features","volume":"13","author":"Pollari","year":"2021","journal-title":"Cancers"},{"key":"B11","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3390\/biomedicines8060170","article-title":"Ror1 is expressed in diffuse large B-cell lymphoma (Dlbcl) and a small molecule inhibitor of ror1 (Kan0441571c) induced apoptosis of lymphoma cells","volume":"8","author":"Ghaderi","year":"2020","journal-title":"Biomedicines"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011366","article-title":"Immune evasion in primary testicular and central nervous system lymphomas: hla loss rather than 9p24.1\/pd-L1\/pd-L2 alterations","volume":"138","author":"Minderman","year":"2021","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2017.12.001","article-title":"The pathobiology of primary testicular diffuse large B-cell lymphoma: implications for novel therapies","volume":"32","author":"Twa","year":"2018","journal-title":"Blood Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004212","article-title":"The molecular hallmarks of primary and secondary vitreoretinal lymphoma","volume":"6","author":"Bonzheim","year":"2022","journal-title":"Blood Adv"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05301-7","article-title":"Clinicopathological analysis and specific discriminating markers of interleukin detection in cerebrospinal fluid with primary central nervous system lymphoma: results from a retrospective study","volume":"102","author":"Li","year":"2023","journal-title":"Ann Hematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104042","article-title":"Challenges in the management of primary central nervous system lymphoma","volume":"188","author":"Sun","year":"2023","journal-title":"Crit Rev Oncology\/hematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.01.042","article-title":"Logistic regression classification of primary vitreoretinal lymphoma versus uveitis by interleukin 6 and interleukin 10 levels","volume":"127","author":"Kuo","year":"2020","journal-title":"Ophthalmology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2023.12.001","article-title":"Diagnostic methods for primary vitreoretinal lymphoma: A systematic review","volume":"69","author":"Huang","year":"2024","journal-title":"Survey Ophthalmol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.21037\/aol-20-53","article-title":"Primary central nervous system lymphoma: advances in mri and pet imaging","volume":"5","author":"Ambady","year":"2021","journal-title":"Ann Lymphoma"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.811197","article-title":"Differentiation between primary central nervous system lymphoma and atypical glioblastoma based on mri morphological feature and signal intensity ratio: A retrospective multicenter study","volume":"12","author":"Han","year":"2022","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.radcr.2020.12.003","article-title":"Imaging of primary testicular lymphoma with unusual intraabdominal spread along the spermatic cord and gonadal vein","volume":"16","author":"Kumar Madaan","year":"2021","journal-title":"Radiol Case Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2022.101053","article-title":"Challenges in the diagnosis and management of vitreoretinal lymphoma - clinical and basic approaches","volume":"90","author":"Takase","year":"2022","journal-title":"Prog Retinal Eye Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29100543","article-title":"Primary vitreoretinal lymphoma: current diagnostic laboratory tests and new emerging molecular tools","volume":"29","author":"Melli","year":"2022","journal-title":"Curr Oncol (Toronto Ont.)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.clml.2021.03.011","article-title":"Diagnostic performance of pretreatment 18f-fluorodeoxyglucose positron emission tomography with or without computed tomography in patients with primary central nervous system lymphoma: updated systematic review and diagnostic test accuracy meta-analyses","volume":"21","author":"Gupta","year":"2021","journal-title":"Clin Lymphoma Nyeloma Leukemia"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab234","article-title":"Body ct and pet\/ct detection of extracranial lymphoma in patients with newly diagnosed central nervous system lymphoma","volume":"24","author":"Hyun Suh","year":"2022","journal-title":"Neuro-oncology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000020140","article-title":"Clinicopathological characteristics of primary central nervous system lymphoma with low 18f-fludeoxyglucose uptake on brain positron emission tomography","volume":"99","author":"Kim","year":"2020","journal-title":"Medicine"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06334-w","article-title":"18f]Fdg pet-mri provides survival biomarkers in primary central nervous system lymphoma in the elderly: an ancillary study from the blocage trial of the loc network","volume":"50","author":"Rozenblum","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab020","article-title":"Consensus recommendations for mri and pet imaging of primary central nervous system lymphoma: guideline statement from the international primary cns lymphoma collaborative group (Ipcg)","volume":"23","author":"Barajas","year":"2021","journal-title":"Neuro-oncology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221093745","article-title":"Novel insights into the biomarkers and therapies for primary central nervous system lymphoma","volume":"14","author":"Zhai","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.241208","article-title":"Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas","volume":"106","author":"Bobillo","year":"2021","journal-title":"Haematologica"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279908","article-title":"A pilot study of the use of dynamic analysis of cell-free DNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas","volume":"107","author":"Wang","year":"2022","journal-title":"Haematologica"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.3390\/cancers11111647","article-title":"Tumor and cerebrospinal fluid micrornas in primary central nervous system lymphomas","volume":"11","author":"Zajdel","year":"2019","journal-title":"Cancers"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.3390\/jcm9061844","article-title":"High-throughput microrna profiling of vitreoretinal lymphoma: vitreous and serum microrna profiles distinct from uveitis","volume":"9","author":"Minezaki","year":"2020","journal-title":"J Clin Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.11.002","article-title":"Molecular and clinical diversity in primary central nervous system lymphoma","volume":"34","author":"Hern\u00e1ndez-Verdin","year":"2023","journal-title":"Ann Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13045-022-01356-7","article-title":"Evidence-based expert consensus on the management of primary central nervous system lymphoma in China","volume":"15","author":"Chen","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","article-title":"Roles of pd-1\/pd-L1 pathway: signaling, cancer, and beyond","volume":"1248","author":"Ai","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-764209","article-title":"Pd-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.02.012","article-title":"Checking in on lenalidomide in diffuse large B cell lymphoma","volume":"19","author":"Goldfinger","year":"2019","journal-title":"Clin Lymphoma Nyeloma Leukemia"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2174\/1871524914999140818111514","article-title":"Novel agents in cns myeloma treatment","volume":"14","author":"Gozzetti","year":"2014","journal-title":"Cent Nervous Syst Agents Ned Chem"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024168","article-title":"Glofitamab stimulates immune cell infiltration of cns tumors and induces clinical responses in secondary cns lymphoma","volume":"144","author":"Godfrey","year":"2024","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27316","article-title":"Car T-cell therapy induces a high rate of prolonged remission in relapsed primary cns lymphoma: real-life results of the loc network","volume":"99","author":"Choquet","year":"2024","journal-title":"Am J Hematol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008525","article-title":"Toxicity and efficacy of car T-cell therapy in primary and secondary cns lymphoma: A meta-analysis of 128 patients","volume":"7","author":"Cook","year":"2023","journal-title":"Blood Adv"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-024-2685-9","article-title":"Unlocking the potential: advancements and future horizons in ror1-targeted cancer therapies","volume":"67","author":"Li","year":"2024","journal-title":"Sci China Life Sci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.1c02996","article-title":"Reversibly modulating the blood-brain barrier by laser stimulation of molecular-targeted nanoparticles","volume":"21","author":"Li","year":"2021","journal-title":"Nano Lett"},{"key":"B45","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.chembiol.2023.09.008","article-title":"Bispecific antibody shuttles targeting cd98hc mediate efficient and long-lived brain delivery of iggs","volume":"31","author":"Pornnoppadol","year":"2024","journal-title":"Cell Chem Biol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-023-03292-5","article-title":"Prognostic value of pod18 combined with improved ielsg in primary central nervous system lymphoma","volume":"26","author":"Du","year":"2024","journal-title":"Clin Trans Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2926","article-title":"Combined tumor-associated macrophages biomarker predicting extremely poor outcome of patients with primary central nervous system lymphoma","volume":"39","author":"Sun","year":"2021","journal-title":"Hematol Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.696147","article-title":"A novel prognostic marker for primary cns lymphoma: lactate dehydrogenase-to-lymphocyte ratio improves stratification of patients within the low and intermediate mskcc risk groups","volume":"11","author":"Gao","year":"2021","journal-title":"Front Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1104425","article-title":"A novel inflammation-related prognostic model for predicting the overall survival of primary central nervous system lymphoma: A real-world data analysis","volume":"13","author":"Wu","year":"2023","journal-title":"Front Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-023-04337-z","article-title":"A novel prognostic model based on pretreatment serum albumin and ecog ps for primary cns lymphoma: an international, multi-center study","volume":"163","author":"Wei","year":"2023","journal-title":"J Neuro-oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2872","article-title":"A new prognostic score for disease progression and mortality in patients with newly diagnosed primary cns lymphoma","volume":"9","author":"Liu","year":"2020","journal-title":"Cancer Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s11684-023-0994-x","article-title":"Analysis of the genomic landscape of primary central nervous system lymphoma using whole-genome sequencing in chinese patients","volume":"17","author":"Yuan","year":"2023","journal-title":"Front Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.3390\/cancers14071818","article-title":"A prognostic model using post-steroid neutrophil-lymphocyte ratio predicts overall survival in primary central nervous system lymphoma","volume":"14","author":"Lo","year":"2022","journal-title":"Cancers"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.2147\/jir.S341355","article-title":"The mutation of btg2 gene predicts a poor outcome in primary testicular diffuse large B-cell lymphoma","volume":"15","author":"Guo","year":"2022","journal-title":"J\u00a0Inflammation Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.2147\/ott.S228746","article-title":"Prognostic significance of ldh ratio in serum\/cerebral spinal fluid of patients with primary testicular diffuse large B-cell lymphoma","volume":"12","author":"Liu","year":"2019","journal-title":"OncoTargets Ther"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.65517","article-title":"Loss of 5-hydroxymethylcytosine as a poor prognostic factor for primary testicular diffuse large B-cell lymphoma","volume":"19","author":"Shen","year":"2022","journal-title":"Int J Med Sci"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-020-00864-6","article-title":"The role of immunohistochemical overexpression of P53 as adverse prognostic factor in primary testicular diffuse large B cell lymphoma","volume":"26","author":"Hatzl","year":"2020","journal-title":"Pathol Oncol Res: POR"},{"key":"B58","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1186\/s12967-024-05140-8","article-title":"Genomic landscape and distinct molecular subtypes of primary testicular lymphoma","volume":"22","author":"Zhang","year":"2024","journal-title":"J Trans Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.200105","article-title":"T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma","volume":"104","author":"Leivonen","year":"2019","journal-title":"Haematologica"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.3390\/jcm9072298","article-title":"Identification of prognostic markers in patients with primary vitreoretinal lymphoma by clustering analysis using clinical data","volume":"9","author":"Tsubota","year":"2020","journal-title":"J Clin Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.760405","article-title":"Preliminary evaluation of zanubrutinib-containing regimens in dlbcl and the cerebrospinal fluid distribution of zanubrutinib: A 13-case series","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-21-50","article-title":"Bruton\u2019s tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution","volume":"10","author":"Yu","year":"2021","journal-title":"Trans Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1186\/s12885-019-5741-y","article-title":"Intracranial antitumor responses of nivolumab and ipilimumab: A pharmacodynamic and pharmacokinetic perspective, a scoping systematic review","volume":"19","author":"Van Bussel","year":"2019","journal-title":"BMC Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04893-w","article-title":"Low cerebrospinal fluid-to-plasma ratios of orally administered lenalidomide mediated by its low cell membrane permeability in patients with hematologic Malignancies","volume":"101","author":"Ogiya","year":"2022","journal-title":"Ann Hematol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071754","article-title":"Pomalidomide shows significant therapeutic activity against cns lymphoma with a major impact on the tumor microenvironment in murine models","volume":"8","author":"Li","year":"2013","journal-title":"PloS One"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05797-7","article-title":"Clinical characteristics and prognosis of patients with newly diagnosed primary central nervous system lymphoma: A multicenter retrospective analysis","volume":"103","author":"Bai","year":"2024","journal-title":"Ann Hematol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.901797","article-title":"Orelabrutinib combined with lenalidomide and immunochemotherapy for relapsed\/refractory primary central nervous system lymphoma: A retrospective analysis of case series","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.938421","article-title":"Pemetrexed plus lenalidomide for relapsed\/refractory primary central nervous system lymphoma: A prospective single-arm phase ii study","volume":"12","author":"Ma","year":"2022","journal-title":"Front Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdae037","article-title":"Three-year follow-up analysis of phase 1\/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma","volume":"6","author":"Yonezawa","year":"2024","journal-title":"Neuro-oncol Adv"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004779","article-title":"A phase 1\/2 study of thiotepa-based immunochemotherapy in relapsed\/refractory primary cns lymphoma: the tier trial","volume":"5","author":"Fox","year":"2021","journal-title":"Blood Adv"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-835496","article-title":"Phase 1 study of pomalidomide and dexamethasone for relapsed\/refractory primary cns or vitreoretinal lymphoma","volume":"132","author":"Tun","year":"2018","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz032","article-title":"Lenalidomide in combination with intravenous rituximab (Revri) in relapsed\/refractory primary cns lymphoma or primary intraocular lymphoma: A multicenter prospective \u2018Proof of concept\u2019 Phase ii study of the french oculo-cerebral lymphoma (Loc) network and the lymphoma study association (Lysa)\u2020","volume":"30","author":"Ghesquieres","year":"2019","journal-title":"Ann Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008553","article-title":"Real-world experience of commercial relmacabtagene autoleucel (Relma-cel) for relapsed\/refractory central nervous system lymphoma: A multicenter retrospective analysis of patients in China","volume":"12","author":"Yu","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285613","article-title":"Outcomes of patients with primary central nervous system lymphoma following cd19-targeted chimeric antigen receptor T-cell therapy","volume":"110","author":"Mercadal","year":"2024","journal-title":"Haematologica"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014738","article-title":"Safety and efficacy of tisagenlecleucel in primary cns lymphoma: A phase 1\/2 clinical trial","volume":"139","author":"Frigault","year":"2022","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad118","article-title":"Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with cd19-directed chimeric antigen receptor T-cells","volume":"25","author":"Karschnia","year":"2023","journal-title":"Neuro-oncology"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.282875","article-title":"Car T-cell therapy for central nervous system lymphomas: blood and cerebrospinal fluid biology, and outcomes","volume":"108","author":"Lacan","year":"2023","journal-title":"Haematologica"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1533444\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T02:24:54Z","timestamp":1740536694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1533444\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":77,"alternative-id":["10.3389\/fimmu.2025.1533444"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1533444","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"article-number":"1533444"}}